Pulmonary hypertension: Updating a mysterious disease

Cardiovascular Research

Volumn 34, Issue 2, 1997, Pages 268-272

  Rabinovitch, Marlene ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

AML I; Elastase; Elastin; Pulmonary hypertension; Systemic vascular disease

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; ELASTASE; MATRIX PROTEIN; MESSENGER RNA; TENASCIN; TRANSFORMING GROWTH FACTOR BETA; VON WILLEBRAND FACTOR;

CONGENITAL HEART MALFORMATION; ENZYME ACTIVITY; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATORY CELL; LUNG ANGIOGRAPHY; LUNG ARTERY PRESSURE; LUNG BIOPSY; LUNG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANIMALS; ENDOTHELIUM, VASCULAR; GROWTH SUBSTANCES; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; MUSCLE, SMOOTH, VASCULAR; PANCREATIC ELASTASE; PLANT OILS; SCHISTOSOMIASIS;

EID: 0030914613     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(97)00053-9     Document Type: Review

References (31)

1. Rabinovitch, M., Pathophysiology of pulmonary hypertension. 5th ed. Baltimore: Williams and Wilkins, 1995:1659-1695.
2. Heath D, Edwards J. The pathology of hypertensive pulmonary vascular disease. Circulation 1958;18:533-547.
3. Rabinovitch M, Konstam MA, Gamble WJ, et al. Changes in pulmonary blood flow affect vascular response to chronic hypoxia in rats. Circ Res 1983;52:432-441.
4. Rosenberg HC, Rabinovitch M. Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension. Am J Physiol 1988;255:H1484-H1491.
5. Prosser I, Stenmark K, Suthar M, Crouch E, Mecham R, Parks W. Regional heterogeneity of elastin and collagen gene expression in intralobar arteries in response to hypoxic pulmonary hypertension as demonstrated by in situ hybridization. Am J Pathol 1989;135(6):1073-1088.
6. Voelkel NF, Tuder RM, Bridges J, Arend WP. Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. Am J Respir Cell Mol Biol 1994;11:664-675.
7. Rabinovitch M, Bothwell T, Mullen M, Hayakawa BN. High-pressure pulsation of central and microvessel pulmonary artery endothelial cells. Am J Physiol 1988;254:C338-C343.
8. Rabinovitch M, Andrew M, Thom H, et al. Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart defects. Circulation 1987;76(5):1043-1052.
9. Turner-Gomes SO, Andrew M, Coles J, Trusler GA, Williams WG, Rabinovitch M. Abnormalities in von Willebrand factor and anti-thrombin III after cardiopulmonary bypass operations for congenital heart disease. Thorac Cardiovasc Surg 1992;103:87-97.
10. Meyrick BO, Niedermeyer ME, Ogletree ML, Brigham KL. Pulmonary hypertension and increased vasoreactivity caused by repeated indomethacin in sheep. J Appl Physiol 1985;59:443-452.
11. Kobayashi J, Wigle D, Childs T, Zhu L, Keeley FW, Rabinovitch M. Serum-induced vascular smooth muscle cell elastolytic activity through tyrosine kinase intracellular signaling. J Cell Physiol 1994;160:121-131.
12. Hornebeck W, Brechemier D, Soleilhac JM, Bourdillon MC, Robert L. Studies on rat aorta smooth muscle cells' elastase activity. In: Reddi A, editor. Extracellular matrix: structure and function, vol 25. New York: Alan R. Liss, Inc., 1985:269-282.
13. Sato Y, Rifkin DB. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: Activation of a latent transforming growth factor-β1-like molecule by plasmin during co-culture. J Cell Biol 1989;109:309-315.
14. Thompson K, Rabinovitch M. Exogenous leukocyte and endogenous elastases can mediate mitogenic activity in pulmonary artery smooth muscle cells by release of extracellular matrix-bound basic fibroblast growth factor. J Cell Physiol 1995;166:495-505.
15. Perkett EA, Lyons RM, Moses HL, Brigham KL, Meyrick B. Transforming growth factor β activity in sheep lung lymph during the development of pulmonary hypertension. J Clin Invest 1990;86:1459-1464.
16. Botney MD, Bahadori L, Gold LI. Vascular remodeling in primary pulmonary hypertension. Potential role for transforming growth factor-β. Am J Pathol 1994;144(2):286-295.
17. Tucker RP, Hammarback JA, Jenrath DA, Mackie EJ, Xu Y. Tenascin expression in the mouse: in situ localization and induction in vitro by bFGF. J Cell Sci 1993;104:69-76.
18. Hinek A, Molossi S, Rabinovitch M. Functional interplay between interleukin-1 receptor and elastin binding protein controls fibronectin synthesis in coronary artery smooth muscle cells. Exp Cell Res 1996;225:122-131.
19. Boudreau N, Turley E, Rabinovitch M. Fibronectin, hyaluronan and a hyaluronan binding protein contribute to increased ductus arteriosus smooth muscle cell migration. Dev Biol 1991;143:235-247.
20. Zhou B, Rabinovitch M. Partial purification of cytoplasmic factors that bind to an AU rich element in 3′ untranslated region of fibronectin mRNA. Molec Biol Cell 1995;(suppl)6:79a.
21. Todorovich-Hunter L, Dodo H, Ye C, McCready L, Keeley FW, Rabinovitch M. Increased pulmonary artery elastolytic activity in adult rats with monocrotaline-induced progressive hypertensive pulmonary vascular disease compared with infant rats with nonprogressive disease. Am Rev Respir Dis 1992;146:213-223.
22. Maruyama K, Ye C, Woo M, et al. Chronic hypoxic pulmonary hypertension in rats and increased elastolytic activity. Am J Physiol 1991;261:H1716-H1726.
23. Ye C, Rabinovitch M. Inhibition of elastolysis by SC-37698 reduces development and progression of monocrotaline pulmonary hypertension. Am J Physiol 1991;261:H1255-H1267.
24. Zhu L, Wigle D, Hinek A, et al. The endogenous vascular elastase that governs development and progression of monocrotaline-induced pulmonary hypertension in rats is a novel enzyme related to the serine proteinase adipsin. J Clin Invest 1994;94:1163-1171.
25. Jones PL, Rabinovitch M. Tenascin-C induced with progressive pulmonary vascular disease in rats is functionally related to increased smooth muscle cell proliferation. Circ Res 1996;79:1131-1142.
26. Liptay MJ, Parks WC, Mecham RP, et al. Neointimal macrophages colocalize with extracellular matrix gene expression in human atherosclerotic pulmonary arteries. J Clin Invest 1993;91:588-594.
27. Barst RJ, Flaster ER, Menon A, Fotino M, Morse JH. Evidence for the association of unexplained pulmonary hypertension in children with the major histocompatibility complex. Circulation 1992;85:249-258.
28. Stelzner TJ, O'Brien RF, Yanigisawa M, et al. Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension. Am J Physiol 1992;262(5 Pt 1):L614-L620.
29. Bando K, Armitage JM, Paradis IL, et al. Indications for and results of single, bilateral, and heart-lung transplantation for pulmonary hypertension. J Thorac Cardiovasc Surg 1994;108:1056-1065.
30. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121:409-415.
31. Cowan B, Baron O, Crack J, Coulber C, Wilson GJ, Rabinovitch M. Elafin, a serine elastase inhibitor, attenuates post-cardiac transplant coronary arteriopathy and reduces mycardial necrosis in rabbits after heterotopic cardiac transplantation. J Clin Invest 1996;97:2452-2468.